HIGHLIGHTS
- who: Andreas Hochhaus from the (UNIVERSITY) have published the paper: Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL, in the Journal: (JOURNAL) of 12/01/2023
- what: Briefly, asciminib demonstrated statistically significant superior efficacy and better safety and tolerability vs bosutinib: the major molecular response (MMR, BCR::ABL1IS u2264 0.1%) rate at week 24 nearly doubled with asciminib compared with bosutinib (25.5% vs 13.2%); the MMR rate difference between arms, adjusted for baseline major cytogenetic response . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.